Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer is an aggressive disease with increasing global incidence in recent years.
Human epidermal growth receptor 2 (HER2) is overexpressed in approximately 10–20% of …

ABSTRACT IMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the
cancer-associated gastric-lineage marker CLDN18. 2, has recently been reported to have …

Background Claudin18. 2 (CLDN18. 2) is a tight junction protein that has been identified as
a clinically proven target in gastric cancer. Stimulation of 4-1BB with agonistic antibodies is …

Background The addition of nivolumab to chemotherapy improves survival in patients with
advanced oesophagogastric (oesophageal, gastric, or gastro-oesophageal junction) …

Claudin18. 2 has been recently recognized as a potential therapeutic target for gastric/
gastroesophageal junction or pancreatic cancer. Here, we develop a Claudin18. 2-directed …

Gastric cancer is a heterogeneous disease with diverse histological and genomic subtypes,
making it difficult to demonstrate treatment efficacy in clinical trials. However, recent efforts …

Claudin 18.2 has emerged as a promising therapeutic target in gastric cancer based on
phase 3 studies. However, clinicopathologic features associated with claudin 18.2 …

Simple Summary Gastric cancer is a deadly disease with worldwide prevalence that is often
diagnosed at late stages. About two-thirds of patients in Western countries will present with …

Clinical trials frequently include multiple end points that mature at different times. The initial
report, typically based on the primary end point, may be published when key planned co …